159 related articles for article (PubMed ID: 31930735)
21. New insights into human lysine degradation pathways with relevance to pyridoxine-dependent epilepsy due to antiquitin deficiency.
Crowther LM; Mathis D; Poms M; Plecko B
J Inherit Metab Dis; 2019 Jul; 42(4):620-628. PubMed ID: 30767241
[TBL] [Abstract][Full Text] [Related]
22. Normal plasma pipecolic acid level in pyridoxine dependent epilepsy due to ALDH7A1 mutations.
Mercimek-Mahmutoglu S; Donner EJ; Siriwardena K
Mol Genet Metab; 2013; 110(1-2):197. PubMed ID: 23683770
[No Abstract] [Full Text] [Related]
23. Pyridoxine-dependent epilepsy due to antiquitin deficiency: achieving a favourable outcome.
Oliveira R; Pereira C; Rodrigues F; Alfaite C; Garcia P; Robalo C; Fineza I; Gonçalves O; Struys E; Salomons G; Jakobs C; Diogo L
Epileptic Disord; 2013 Dec; 15(4):400-6. PubMed ID: 24184718
[TBL] [Abstract][Full Text] [Related]
24. A novel mouse model for pyridoxine-dependent epilepsy due to antiquitin deficiency.
Al-Shekaili HH; Petkau TL; Pena I; Lengyell TC; Verhoeven-Duif NM; Ciapaite J; Bosma M; van Faassen M; Kema IP; Horvath G; Ross C; Simpson EM; Friedman JM; van Karnebeek C; Leavitt BR
Hum Mol Genet; 2020 Nov; 29(19):3266-3284. PubMed ID: 32969477
[TBL] [Abstract][Full Text] [Related]
25. Pyridoxine-dependent epilepsy with elevated urinary α-amino adipic semialdehyde in molybdenum cofactor deficiency.
Struys EA; Nota B; Bakkali A; Al Shahwan S; Salomons GS; Tabarki B
Pediatrics; 2012 Dec; 130(6):e1716-9. PubMed ID: 23147983
[TBL] [Abstract][Full Text] [Related]
26. LC-MS/MS method for the differential diagnosis of treatable early onset inherited metabolic epilepsies.
Mathis D; Beese K; Rüegg C; Plecko B; Hersberger M
J Inherit Metab Dis; 2020 Sep; 43(5):1102-1111. PubMed ID: 32319100
[TBL] [Abstract][Full Text] [Related]
27. Human pyrroline-5-carboxylate reductase (PYCR1) acts on Δ(1)-piperideine-6-carboxylate generating L-pipecolic acid.
Struys EA; Jansen EE; Salomons GS
J Inherit Metab Dis; 2014 May; 37(3):327-32. PubMed ID: 24431009
[TBL] [Abstract][Full Text] [Related]
28. Current knowledge for pyridoxine-dependent epilepsy: a 2016 update.
Pena IA; MacKenzie A; Van Karnebeek CDM
Expert Rev Endocrinol Metab; 2017 Jan; 12(1):5-20. PubMed ID: 30058881
[TBL] [Abstract][Full Text] [Related]
29. Metabolomics analysis of antiquitin deficiency in cultured human cells and plasma: Relevance to pyridoxine-dependent epilepsy.
Crowther LM; Poms M; Zandl-Lang M; Abela L; Hartmann H; Seiler M; Mathis D; Plecko B
J Inherit Metab Dis; 2023 Jan; 46(1):129-142. PubMed ID: 36225138
[TBL] [Abstract][Full Text] [Related]
30. Metabolite Identification Using Infrared Ion Spectroscopy─Novel Biomarkers for Pyridoxine-Dependent Epilepsy.
van Outersterp RE; Engelke UFH; Merx J; Berden G; Paul M; Thomulka T; Berkessel A; Huigen MCDG; Kluijtmans LAJ; Mecinović J; Rutjes FPJT; van Karnebeek CDM; Wevers RA; Boltje TJ; Coene KLM; Martens J; Oomens J
Anal Chem; 2021 Nov; 93(46):15340-15348. PubMed ID: 34756024
[TBL] [Abstract][Full Text] [Related]
31. Simple, fast and inexpensive quantification of glycolate in the urine of patients with primary hyperoxaluria type 1.
Boehm T; Martin-Higueras C; Friesser E; Zitta C; Wallner S; Walli A; Kovacevic K; Hubmann H; Klavins K; Macheroux P; Hoppe B; Jilma B
Urolithiasis; 2023 Mar; 51(1):49. PubMed ID: 36920530
[TBL] [Abstract][Full Text] [Related]
32. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy.
Gallagher RC; Van Hove JL; Scharer G; Hyland K; Plecko B; Waters PJ; Mercimek-Mahmutoglu S; Stockler-Ipsiroglu S; Salomons GS; Rosenberg EH; Struys EA; Jakobs C
Ann Neurol; 2009 May; 65(5):550-6. PubMed ID: 19142996
[TBL] [Abstract][Full Text] [Related]
33. A Prospective Case Study of the Safety and Efficacy of Lysine-Restricted Diet and Arginine Supplementation Therapy in a Patient With Pyridoxine-Dependent Epilepsy Caused by Mutations in ALDH7A1.
Mahajnah M; Corderio D; Austin V; Herd S; Mutch C; Carter M; Struys E; Mercimek-Mahmutoglu S
Pediatr Neurol; 2016 Jul; 60():60-5. PubMed ID: 27212567
[TBL] [Abstract][Full Text] [Related]
34. Lysine-restricted diet and mild cerebral serotonin deficiency in a patient with pyridoxine-dependent epilepsy caused by
Mercimek-Mahmutoglu S; Corderio D; Nagy L; Mutch C; Carter M; Struys E; Kyriakopoulou L
Mol Genet Metab Rep; 2014; 1():124-128. PubMed ID: 27896080
[TBL] [Abstract][Full Text] [Related]
35. An intriguing "silent" mutation and a founder effect in antiquitin (ALDH7A1).
Salomons GS; Bok LA; Struys EA; Pope LL; Darmin PS; Mills PB; Clayton PT; Willemsen MA; Jakobs C
Ann Neurol; 2007 Oct; 62(4):414-8. PubMed ID: 17721876
[TBL] [Abstract][Full Text] [Related]
36. Delta-1-piperideine-6-carboxylate dehydrogenase, a new enzyme that forms alpha-aminoadipate in Streptomyces clavuligerus and other cephamycin C-producing actinomycetes.
de La Fuente JL; Rumbero A; Martín JF; Liras P
Biochem J; 1997 Oct; 327 ( Pt 1)(Pt 1):59-64. PubMed ID: 9355735
[TBL] [Abstract][Full Text] [Related]
37. Novel therapy for pyridoxine dependent epilepsy due to ALDH7A1 genetic defect: L-arginine supplementation alternative to lysine-restricted diet.
Mercimek-Mahmutoglu S; Cordeiro D; Cruz V; Hyland K; Struys EA; Kyriakopoulou L; Mamak E
Eur J Paediatr Neurol; 2014 Nov; 18(6):741-6. PubMed ID: 25127453
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the first knock-out aldh7a1 zebrafish model for pyridoxine-dependent epilepsy using CRISPR-Cas9 technology.
Zabinyakov N; Bullivant G; Cao F; Fernandez Ojeda M; Jia ZP; Wen XY; Dowling JJ; Salomons GS; Mercimek-Andrews S
PLoS One; 2017; 12(10):e0186645. PubMed ID: 29053735
[TBL] [Abstract][Full Text] [Related]
39. Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy: Neurodevelopmental outcome.
Coughlin CR; van Karnebeek CD; Al-Hertani W; Shuen AY; Jaggumantri S; Jack RM; Gaughan S; Burns C; Mirsky DM; Gallagher RC; Van Hove JL
Mol Genet Metab; 2015; 116(1-2):35-43. PubMed ID: 26026794
[TBL] [Abstract][Full Text] [Related]
40. Clinical, biochemical, and molecular studies in pyridoxine-dependent epilepsy. Antisense therapy as possible new therapeutic option.
Pérez B; Gutiérrez-Solana LG; Verdú A; Merinero B; Yuste-Checa P; Ruiz-Sala P; Calvo R; Jalan A; Marín LL; Campos O; Ruiz MÁ; San Miguel M; Vázquez M; Castro M; Ferrer I; Navarrete R; Desviat LR; Lapunzina P; Ugarte M; Pérez-Cerdá C
Epilepsia; 2013 Feb; 54(2):239-48. PubMed ID: 23350806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]